Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 14/20 | 0.48 |
| ▸ | LOX | P28300 | 4/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8546451 | 0.85 | LOXL2 (0.45) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL25487504 | 0.83 | LOXL2 (0.48) | LOXL2LOXMERTKMETKHK | |
| SCHEMBL22622482 | 0.82 | LOXL2 (0.60) | LOXL2LOXMET | |
| SCHEMBL23129193 | 0.82 | AXL (0.49) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL18236180 | 0.81 | TYRO3 (0.48) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL22449871 | 0.80 | AXL (0.48) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL24268229 | 0.80 | AXL (0.48) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL27315685 | 0.79 | AXL (0.38) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL22449715 | 0.78 | LOXL2 (0.47) | LOXL2LOXAXLTYRO3MERTK | |
| SCHEMBL22449699 | 0.77 | LOXL2 (0.46) | LOXL2LOXAXLMERTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183789-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | Incyte Holdings Corporation (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3129021-B1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORP (US) | 2020-09-23 | — | — | EP | disclosed |